# MarQed.ai RLVR Platform Strategy
## Management Samenvatting & Investeringsvoorstel

**Auteur:** Eddie Zeen, ROSK Consulting / MarQed.ai  
**Datum:** 4 januari 2025  
**Status:** Investeringsbeslissing - Go/No-Go Q1 2025

---

## Executive Summary

MarQed.ai staat op het punt van een strategische transformatie: van traditionele code-analyse naar de **eerste AI-native legacy modernization platform** in Europa, aangedreven door Large Reasoning Models (LRM) met Reinforcement Learning from Verifiable Rewards (RLVR). Deze investering positioneert ons als **frontrunner in AI-gedreven healthcare IT modernization** met een defensieve marktpositie voordat grote Amerikaanse spelers (Mobilize.Net, Stride 100x) de Europese markt betreden.

---

## Waarom LRM's in plaats van LLM's?

### Het Paradigmaverschuiving: Reasoning > Generation

**Traditional LLM's (Large Language Models):**
- Genereren code op basis van patronen
- Geen self-verification capability
- Accuracy: 70-85% (veel handmatige correctie nodig)
- Static: leren niet van fouten

**LRM's (Large Reasoning Models) met RLVR:**
- **Redeneren** over code transformaties stap-voor-stap (Chain-of-Thought)
- **Self-verification:** agent controleert eigen output, corrigeert fouten automatisch
- **Accuracy: 95%+** (DeepSeek R1 bewijst dit op math/code benchmarks)
- **Self-learning:** verbeteren via reinforcement learning uit productie feedback

**Concreet verschil voor MarQed.ai:**
- **LLM-approach:** AI genereert code → developer test → bugs → handmatig fixen → herhaal (weken werk)
- **LRM-approach:** AI genereert code → AI test zelf → AI fix bugs → AI verifieert → klaar voor review (uren werk)

**Impact:** 40-50% sneller, 60% goedkoper, 95% accuracy vs 85% industry standard.

**Bewijs:** DeepSeek R1 (januari 2025) toont gold-level performance op wiskunde competities, 96.3% op Codeforces. Dit is geen toekomstmuziek—**de technologie is productie-ready**.

---

## De Markt & Onze Timing

**Global Market:** €500B legacy modernization by 2027 (Gartner, McKinsey)  
**NL Healthcare:** €10-35M addressable (50-70 hospitals need EPD modernization)  
**Market Window:** 12-18 maanden voordat GAP/Stride EU betreden

**Concurrentie Status:**
- **NL:** Geen AI-native spelers (SUE's Re:App = black box, Radorfa/Toomba = manual)
- **EU:** ModLogix, PASS = tools-only of traditionele consulting (geen LRM)
- **US:** Stride 100x, Rhino.ai = AI-first maar generalist, niet healthcare
- **Israel:** Geen legacy modernization focus (security/cloud/AI infrastructure)

**MarQed.ai Unique Position:** 
Eerste en enige LRM-platform met **NEN7510 compliance automation** + **healthcare domain expertise** + **RLVR self-correction** in Europa.

---

## Investeringsvereiste & ROI

### Investering Q1-Q3 2025: €95K
**Breakdown:**
- **Q1 (MVP):** €25K - Pattern recognition agent, self-verification proof
- **Q2 (Pilot):** €30K - Spec generation, architecture design agents
- **Q3 (Production):** €40K - Migration engine, multi-agent ecosystem

**Infrastructuur (Q1-Q3):** €45.7K
- **GPU's:** 2x RTX A5000 (€12K) + 4x RTX 4090 (€8K) = €20K
- **Network/Storage:** 10GbE switch, 20TB NAS = €7K
- **Cloud (Azure):** Training/inference compute = €6K
- **Software:** MLOps tools, licenses = €8K
- **Contingency (15%):** €4.7K

**Totaal Year 1:** €95K (R&D) + €45.7K (infra) = **€140.7K investering**

### Return on Investment

**Revenue Projections:**
- **Year 1:** €750K (10 projecten, break-even maand 8)
- **Year 2:** €2.66M (254% groei)
- **Year 3:** €6.12M (130% groei)

**EBITDA:**
- Year 1: €185K (margin 24.7%)
- Year 2: €1.14M (margin 42.9%)
- Year 3: €3.27M (margin 53.4%)

**Payback Period:** 2-3 maanden per klantproject  
**LTV:CAC Ratio:** 21:1 (excellent)  
**Break-even:** Maand 8 (Year 1)

**Conclusie:** Investering van €140.7K levert €185K EBITDA in Year 1, €1.14M in Year 2. **ROI: 132% (Year 1), 710% (Year 2)**.

---

## Waarom Deze Infrastructuur Nodig Is

### GPU Requirements: LRM's ≠ LLM's

**LRM's vereisen significant meer compute:**
- **Training:** Reinforcement learning = miljoenen trials per model update
- **Inference:** Chain-of-thought reasoning = 3-5x meer tokens dan direct antwoord
- **Self-verification:** Model evalueert eigen output = 2x inference per request

**Concrete VRAM Needs:**
| Model | Precision | Inference | Training | Recommended GPU |
|-------|-----------|-----------|----------|-----------------|
| **DeepSeek R1-7B** | FP16 | 15GB | 30GB+ | RTX A5000 (24GB) |
| **DeepSeek R1-14B** | FP16 | 28GB | 60GB+ | RTX A6000 (48GB) |
| **Production (INT4)** | Quantized | 4-6GB | N/A | RTX 4090 (24GB) |

**Why Not Cloud?**
- **Cost:** €0.50-€2 per hour per GPU (Azure/AWS) = €50-200K/year ongoing
- **Latency:** 100-500ms extra (unacceptable for real-time feedback)
- **Data Privacy:** Healthcare code blijft on-premise (NEN7510 requirement)
- **ROI:** €20K GPU = break-even na 3-4 months vs cloud

**On-Premise = Right Choice:** Capex betaalt zichzelf terug in Q2, daarna pure savings + controle.

---

## Service-First Model: Onze Differentiator

### Managed AI Service (Niet Self-Service Platform)

**Strategie:**
MarQed.ai biedt **"AI-as-a-Service"** aan, niet een self-service tool. Klanten krijgen resultaten, niet toegang tot ons platform.

**Customer Journey:**
1. **Intake:** Klant deelt codebase (secure upload) + requirements
2. **Analysis:** MarQed.ai draait AI agents (achter de schermen)
3. **Dashboard:** Klant ziet progress, quality metrics, insights (read-only)
4. **Delivery:** Klant ontvangt gemigeerde code, documentatie, compliance report
5. **Support:** 90-dagen garantie, MarQed.ai blijft in control

**Voordelen:**
- **Kwaliteitscontrole:** Wij verifiëren AI output voordat klant het ziet (zero hallucinations escape)
- **IP Protection:** Onze RLVR recipes, prompts, models blijven proprietary
- **Customer Success:** Geen learning curve voor klant (wij zijn experts)
- **Upsell Path:** Klanten kunnen niet zonder ons (vendor lock-in door service excellence)

**Multi-Tenant Architectuur:**
- **Data Isolation:** Elke klant = aparte database, aparte AI context (geen cross-contamination)
- **Shared Infrastructure:** AI models, GPU's gedeeld (schaalvoordeel)
- **Compliance:** Per-klant audit trails, toegangscontrole (NEN7510 compliant)

**Future Optionality (Year 2+):**
- **Partner Portal:** EPD vendors (Chipsoft, Epic) krijgen beperkte toegang (co-branding)
- **Customer Self-Service (Premium):** Mature klanten kunnen platform toegang kopen (extra €50K/jaar)
- **API Access:** Developers kunnen MarQed.ai agents aanroepen (usage-based pricing)

**Waarom Service-First Nu:**
1. **Market Maturity:** Healthcare IT is risk-averse, wil hand-holding
2. **Quality Assurance:** AI is 95% maar niet 100%—wij vangen die 5% op
3. **Competitive Moat:** GAP/Stride bieden tools, wij bieden *service*—moeilijk te kopiëren

---

## Competitive Positioning

### MarQed.ai vs The Field

**Ons "Unfair Advantage" Stapel:**
1. **LRM Self-Correction** (unique in markt)
2. **NEN7510 Compliance Automation** (healthcare moat)
3. **Eddie's Domain Expertise** (CISSP/CISM + 1.38M LOC HCI project)
4. **Service-First Model** (tools = commodity, service = differentiation)
5. **European Data Residency** (GDPR/AVG native, US vendors = red tape)

**Market Positioning:**
- **vs Traditional (ModLogix, Redwerk):** 60% goedkoper, 2x sneller, betere kwaliteit
- **vs Tools (GAP, PASS):** Full-service (zij = DIY), learning AI (zij = static rules)
- **vs Emerging AI (Stride, Rhino):** Healthcare specialization (zij = generalist), EU-first (zij = US)

**Positioning Statement:**
*"MarQed.ai is de enige AI-native legacy modernization service met self-correcting LRM's, gebouwd voor NEN7510 compliance, geleverd als managed service door healthcare IT experts."*

**Too Long; Didn't Read:**
*"AI dat veilig, snel en compliant hospital software moderniseert—zonder dat de klant AI hoeft te snappen."*

---

## Risico's & Mitigaties

### Technische Risico's

**Risico 1: RLVR haalt geen 95% accuracy**  
**Likelihood:** LOW (DeepSeek R1 bewezen)  
**Mitigation:** Hybrid model (AI + human review voor kritieke modules)

**Risico 2: GPU costs hoger dan verwacht**  
**Likelihood:** LOW  
**Mitigation:** Quantization (INT4) = 75% VRAM reductie, spot instances backup

### Business Risico's

**Risico 3: Trage markt adoptie (hospitals vertragen)**  
**Likelihood:** MEDIUM  
**Mitigation:** Low-friction Tier 1 entry (€5-10K assessment), pilot programma's

**Risico 4: GAP/Microsoft enters EU healthcare**  
**Likelihood:** MEDIUM (18-24 months)  
**Mitigation:** First-mover advantage (lock in 15-20 hospitals Year 1-2), partnership opportunity

**Risico 5: Key person dependency (Eddie)**  
**Likelihood:** HIGH (Year 1), LOW (Year 2+)  
**Mitigation:** Hire sales engineer Q2, account manager Q3, knowledge transfer

### Overall Risk: MEDIUM-LOW (manageable)

---

## Go/No-Go Decision Criteria

### Q1 Success Metrics (Week 12 Evaluation)

**Must-Have (GO Criteria):**
- ✅ Pattern detection improvement ≥10% vs baseline
- ✅ Self-verification demonstratie (agent corrigeert eigen fouten)
- ✅ Pilot customer secured (Tier 2 or Tier 3)
- ✅ Team confident in tech stack (no major blockers)

**Red Flags (NO-GO Triggers):**
- ❌ Zero improvement over rule-based methods
- ❌ Critical technical failures (GPU memory issues, model instability)
- ❌ Zero customer interest (10+ pitches, 0 conversions)
- ❌ Team wants to quit (morale collapse)

**Decision Point:** Einde Q1 (week 12, ~28 maart 2025)  
**Decision Maker:** Eddie Zeen (founder/CEO)  
**Advisors:** ML Engineer, Backend Engineer, 1-2 external advisors (healthcare CIO's)

---

## Aanbeveling & Volgende Stappen

### Aanbeveling: PROCEED met Q1 MVP Development

**Rationale:**
1. **Market Opportunity Real:** €500B globally, €10-35M NL healthcare, geen AI-native concurrent
2. **Technology Proven:** DeepSeek R1 demonstreert RLVR viability (95%+ accuracy)
3. **Competitive Window Open:** 12-18 maanden om market leadership te claimen
4. **Financial Viability:** Profitable Year 1 (break-even maand 8), no external funding needed
5. **Strategic Fit:** Leverages Eddie's healthcare IT expertise, ROSK relationships, HCI EPD case study

**Timing is Critical:** Als we Q1 skippen, zijn we 6-12 maanden achter op US entrants.

---

### Immediate Actions (Week 1-2, January 2025)

**Week 1:**
1. **Team Alignment:** Review roadmap + business case met ML/Backend engineers (buy-in)
2. **Hardware Order:** Bestellen 2x RTX A5000 (€12K) - levertijd 2-4 weken
3. **Recruitment Start:** Job posting Sales Engineer (start Q2 week 1)
4. **Customer Outreach:** Eddie belt 5 hospital CIO's (gauge interest, seed pipeline)

**Week 2:**
5. **GPU Setup:** P620 configuratie (CUDA, Docker, vLLM, Stable-Baselines3)
6. **Data Prep:** Label 50 ASP Classic samples (Eddie + senior dev)
7. **Open Source Scan:** Monitor Open-R1 project, join Discord/Slack communities
8. **Partner Outreach:** Email Chipsoft/Epic (propose partnership discussion)

---

### Milestones & Checkpoints

**Q1 Checkpoints:**
- **Week 4:** First agent trained (pattern recognition baseline)
- **Week 8:** Self-verification prototype working
- **Week 10:** Pilot customer signed (Tier 2 minimum)
- **Week 12:** GO/NO-GO decision meeting

**Q2 Milestones (if GO):**
- **Week 16:** Spec generation agent deployed
- **Week 20:** Architecture agent validated (expert review)
- **Week 24:** 2 pilot projects delivered, 1 Tier 3 secured

**Q3 Milestones (if Q2 success):**
- **Week 32:** Migration engine production-ready (95% accuracy)
- **Week 36:** 5 full migrations completed
- **Week 38:** Break-even achieved (cumulative revenue > costs)

---

## Conclusie: Waarom Nu Investeren

### De Perfect Storm

**Technology Maturity:** DeepSeek R1 (jan 2025) = LRM's zijn productie-ready  
**Market Need:** NEN7510 2.0 deadline (2026) = hospitals móeten moderniseren  
**Competitive Gap:** Geen AI-native healthcare modernization speler in EU  
**Team Readiness:** Eddie's expertise + HCI EPD proof + ROSK infrastructure  
**Financial Health:** Bootstrap mogelijk (no dilution), break-even maand 8  

**Window is Now:** Als we Q1 starten, zijn we Year 3 market leader met €6M+ revenue en defensieve positie. Als we wachten tot Q3/Q4, zijn US spelers al landed in EU en moeten we vechten om #2 positie.

**Investment Ask:** €140.7K (Q1-Q3 2025)  
**Expected Return:** €185K EBITDA Year 1, €1.14M Year 2, €3.27M Year 3  
**Risk-Adjusted NPV:** €2M+ (3-year horizon, 15% discount rate)

### Final Recommendation

**PROCEED met Q1 MVP als outlined in roadmap.** Market opportunity, technology readiness, team capability, en financial viability zijn aligned. De enige way we *niet* succesvol zijn is als we niet starten.

**Eddie's Decision:** GO / NO-GO (handtekening)

**Datum:** _______________

---

**Bijlagen:**
- Volledige Roadmap (100+ pagina's): marqed-rlvr-roadmap-2025.md
- Business Case (80+ pagina's): marqed-rlvr-business-case-2025.md
- Competitive Analysis Matrix (zie volgende document)

---

*Document Einde - Management Samenvatting (135 regels, 1 A4 equivalent)*
